MedTrace Logo

Study of the Ability of Clarithromycin to Induce Oxidative Stress

NCT00707330 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2008-08-11

No results posted yet for this study

Summary

The purpose of the study is to examine whether Klacid® (Clarithromycin) will induce oxidative stress (stress from oxygen) in healthy subjects. This is done by measuring the content of a particular substance in the urine sample, which is released when the body is exposed to oxidative stress. In addition, there will also be taken blood samples, which is analysed for another substance that is indicative of oxidative stress.

Conditions

  • Oxidative Stress

Interventions

DRUG

Clarithromycin

Prolonged release tablet, 500 mg, 1 tablet a day for a week

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Henrik E Poulsen, dr. med. · Head of Department, Department of Clinical Pharmacology, Rigshospitalet

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • Denmark

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00707330 on ClinicalTrials.gov